secwatch.observer — SEC 8-K summary
======================================

Issuer:     PharmaCyte Biotech, Inc. (PMCB)
CIK:        0001157075
Form:       8-K
Filed at:   2023-09-07T23:59:59+00:00
Accession:  0001683168-23-006331
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PharmaCyte shareholders approve authorized share increase to 200M and financing-related issuance
--------------------------------------------------------------------------------

- Shareholders approved issuance of shares ≥20% of outstanding related to May 2023 Securities Purchase Agreement (convertible preferred & warrants).
- Increase in authorized common stock from 133,333,334 to 200,000,000 approved; amendment filed Sept 6, 2023.
- Quorum: 11,422,363 shares (~68.01%). Proposal 1: 7.17M for, 0.4M against; Proposal 2: 9.98M for, 1.02M against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157075/000168316823006331/0001683168-23-006331-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157075/000168316823006331/pharmacyte_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-23-006331

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer